A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder.

ABSTRACT:

Background

Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants significantly contribute to MOUD outcomes.

Objectives

This systematic review aims to summarize genome-wide significant findings on MOUD outcomes and critically appraise the quality of the studies involved.

Methods

Databases searched from inception until August 21st, 2020 include: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog and GWAS Central. The included studies had to be GWASs that assessed MOUD in an OUD population. All studies were screened in duplicate. The

SUBMITTER: Chawar C 

PROVIDER: S-EPMC8627063 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature